Latest news on Alzheimer's

This interdisciplinary initiative is designed to provide healthcare providers with a set of innovative tools to improve disease identification and management.

Almost 100 participants gathered to discuss the latest advancements in neuroimaging and biomarkers for Alzheimer’s disease, as well as to share updates from the Euro-PAD initiative over the past year.

This fully automated blood test could become a scalable, minimally invasive tool to detect and monitor Alzheimer’s-related changes long before symptoms appear.

With a 3-year duration, this project will allow us to explore the role of neuroinflammation in Alzheimer’s disease using the novel [18F]F-DED PET tracer, in collaboration with LMU Munich and Life Molecular Imaging

We are strengthening our management structure at a time of sustained growth, with more than 250 employees, 6 research groups and a membership base approaching 100,000

The study, published in the journal Alzheimer’s & Dementia, involved 337 people from the ALFA longitudinal cohort of the Barcelonaβeta Brain Research Center (BBRC), with the support of the “la Caixa” Foundation.

In this document we collect the most notable activity of 2024, a year of key scientific advances and new strategic alliances that consolidate a change in the approach to Alzheimer's disease

The group will work with three-dimensional cellular models (organoids) that replicate the structure of the human brain to study the origin and progression of diseases such as Alzheimer’s.

This approval is a key step forward in the development of treatments that target the biological mechanisms of Alzheimer's disease.